443 related articles for article (PubMed ID: 31595568)
1. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
Yanai S; Nakamura S; Kawasaki K; Toya Y; Akasaka R; Oizumi T; Ishida K; Sugai T; Matsumoto T
Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
[TBL] [Abstract][Full Text] [Related]
2. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.
Isidro RA; Ruan AB; Gannarapu S; Raj D; Rahma O; Grover S; Srivastava A
Histopathology; 2021 Mar; 78(4):532-541. PubMed ID: 32931028
[TBL] [Abstract][Full Text] [Related]
3. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
[No Abstract] [Full Text] [Related]
4. From ICI to ICU: Ipilimumab and Nivolumab-Induced Immune Checkpoint Inhibitor Colitis.
Zhou W; Frye J; Soroudi C; Triadafilopoulos G; Berry R
Dig Dis Sci; 2022 Mar; 67(3):800-803. PubMed ID: 34159488
[No Abstract] [Full Text] [Related]
5. Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors.
Yanai S; Toya Y; Sugai T; Matsumoto T
Digestion; 2021; 102(6):965-973. PubMed ID: 34515105
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor induced colitis: A nationwide population-based study.
Farha N; Alkhayyat M; Lindsey A; Mansoor E; Saleh MA
Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101778. PubMed ID: 34332139
[TBL] [Abstract][Full Text] [Related]
7. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
[TBL] [Abstract][Full Text] [Related]
8. Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event.
Yamauchi Y; Arai M; Akizue N; Ohta Y; Okimoto K; Matsumura T; Fan MM; Imai C; Tawada A; Kato J; Kato N; Takiguchi Y
Jpn J Clin Oncol; 2021 Mar; 51(3):363-370. PubMed ID: 33290513
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis.
Nielsen DL; Juhl CB; Chen IM; Kellermann L; Nielsen OH
Cancer Treat Rev; 2022 Sep; 109():102440. PubMed ID: 35917654
[TBL] [Abstract][Full Text] [Related]
10. Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors.
de Andrea CE; Perez-Gracia JL; Castanon E; Ponz-Sarvise M; Echeveste JI; Melero I; Sanmamed MF; Rodriguez-Ruiz ME
Oncoimmunology; 2020 May; 9(1):1760676. PubMed ID: 32934876
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis.
Verschuren EC; van den Eertwegh AJ; Wonders J; Slangen RM; van Delft F; van Bodegraven A; Neefjes-Borst A; de Boer NK
Clin Gastroenterol Hepatol; 2016 Jun; 14(6):836-842. PubMed ID: 26748223
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.
Wang Y; Abu-Sbeih H; Mao E; Ali N; Qiao W; Trinh VA; Zobniw C; Johnson DH; Samdani R; Lum P; Shuttlesworth G; Blechacz B; Bresalier R; Miller E; Thirumurthi S; Richards D; Raju G; Stroehlein J; Diab A
Inflamm Bowel Dis; 2018 Jul; 24(8):1695-1705. PubMed ID: 29718308
[TBL] [Abstract][Full Text] [Related]
13. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
Hammami MB; Gill R; Thiruvengadam N; Oh DY; Beck K; Mahadevan U; Kattah MG
Dig Dis Sci; 2019 Mar; 64(3):685-688. PubMed ID: 30778872
[No Abstract] [Full Text] [Related]
14. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.
Zhang HC; Luo W; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):47. PubMed ID: 30777137
[TBL] [Abstract][Full Text] [Related]
15. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
16. COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.
Holmstroem RB; Nielsen OH; Jacobsen S; Riis LB; Theile S; Bjerrum JT; Vilmann P; Johansen JS; Boisen MK; Eefsen RHL; Marie Svane I; Nielsen DL; Chen IM
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096534
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
Bishu S; Melia J; Sharfman W; Lao CD; Fecher LA; Higgins PDR
Gastroenterology; 2021 Feb; 160(3):932-934.e3. PubMed ID: 33096100
[No Abstract] [Full Text] [Related]
18. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
[TBL] [Abstract][Full Text] [Related]
19. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
[TBL] [Abstract][Full Text] [Related]
20. Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience.
Wei D; Zhou DJ; Datta P; Taraschenko O
Cancer Med; 2021 May; 10(9):2978-2986. PubMed ID: 33660430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
